The auditory brainstem implant (AB/) is a viable treatment option for patients with neurofibromatosis type 2 (NF2 ) whom either vestib ular schwannomas or the surge/y used to remove them has rendered totally deaf This device stimulates the central auditory pathways in a manner similar to the cochlear implant in individuals with a total hearing loss. A multichannel model with transcutaneous signal transmission is in use experimentally in both the United States and Europe . Of 14 patients implanted with the AB1 in a European pilot study, 13 receivedauditory sensations at initial tuning.
Introduction
Until recentl y, the spectre of total deafne ss has threatened patients suffering from neurofibromatosis type 2 (NF2). The bilateral vestibular schwa nnomas-or the surgery to remove them-often cause a complete loss of hearing, usually as a result of damage to the cochlear nerves. In a limited number of cases it is possible to remove small tumors and still preserve useful (i.e., without a hearing aid) or aidable hearing, which is an ideal objective in the management of NF2. In most cases , however, it is not possible to achieve this objective. In other cases it is possible to preserve some hearing by partially removing the tumor, but even if successful, this approac h usually proves to be no more than a tempo rary expedient.
An altern ative opt ion for the rehabilitati on of patients suffering from NF2 is the use of a prostheti c device, the auditory brainstem implant (AB!), which is capable of stimulating the cent ral auditory pathwa ys in a manner similar to the cochl ear implant in those indi vidu als with a total hearing loss from end organ failure. ABI is still at a relatively experimental stage . The first attempts at auditory brainstem impl antation were made by Hou se and Hitselbe rger' r' 17 years ago, using a single-channel prosthesis with percutaneous signal transmission based on the 3M/House cochl ear impl ant. Some early subjects are still using these devices today."
It is common exper ience that multi channel coc hlear implants perform con siderably better than single-channel devices. It has also become clear from several point s of view-safety, reliability and comfort-that transcutaneous signal transmission is preferabl e to the use of a percutaneous plug. Furth ermore, experimental evidence show s some degree of tonotopicity in the coc hlear nucleus com plex (CNC) and has suggested the presenc e of both activating and inhibiting functions. Axons tuned to high frequencies are located dorsally, whereas axons tuned to low frequencies are tuned ventrally. The posteroventral par t of the CNC see ms best suited to the positioning of low-frequency electrodes.' Neurobiologic observa tions of subhuman mamm alian species suggest that the ventral ENT coc hlea r nucl eus (YCN) might have adva ntages ove r the dorsal coc hlear nucleus (DCN) . First, the YCN has a grea ter input of primary aud itory neurones than the DCN . After horseradish peroxidase injection into the cochlea, there is much stronge r labeling in the YCN than in the DCN . Second, the YCN has fewer inhibitory circuits than the DCN and, finally, projects more stro ngly onto the inferior co lliculus."
These facts have led to the developm ent of a mult ichannel auditory prosthesis with transcut aneous signal transmission. Th e Nucl eus Company has taken the initi ative in the design and manufactur e of the se devices and has produced two models, one in use in the United States of America and one in Eur ope. The prototyp e of the European model was first presented at the Iowa Coc hlear Implant Meetin g in 1990 and is undergoing contro lled trial s in Europe. Early experience with the device has been described by the authors .?:"
The main difference between the two designs is in the . numb er of electrodes in the array . The American de vice has eig ht electrodes, whereas the European model comprises a flat, silico ne plate-electrode carrier with 2 1 plat e electrodes (numbers 2 to 22) arranged in three rows (Figu res I and 2). Th e numb er-l electrode is a disc on the back side of the rece iver stimulator. Thi s arrangem ent allows stimulation in the monopolar mode. Th e silico ne plat e mea sures 3 x 8.5 mm , and the indi vidu al electro des are 0.7 mm in diameter, which is large enough to avoid exceeding the critical value s of charge density for neur al tissue.
Surgery
Inserti on of the ABI is usuall y performed at the same time as tum or remova l but might also be done in a separate surgic al procedure at a late r date .'? The transmastoid- translabyrinth ine approach is the preferred rout e, both for tumor remo val and for insert ion of the prosthesis. Th is approac h not only provides the most secure control of the facial nerve, but also avoids cere bellar retraction and allows the mos t direct access to the site of insertion of the ABI in the floo r of the lateral recess of the 4th ventricle.
After tumor remo val, the CNC has to be identifi ed visually, supp orted by monitoring of 7th and 9th cra nial nerve function, and by measurement ofelectrically evoked auditory brainstern potent ials. Thi s is of the grea tes t importance in optimizing the location of the electrode on the CNC. Th e CNC is loc ated in the floor of the lateral recess of the 4th ventricle, and the main guide to its position is the forame n of Luschka ( Figure 3 ). This might , in turn , be found by identifying the choroid plexus, whic h usuall y protrudes from the foramen of Luschka into the cere bellopontine angle. It is help ful to preserve the stump of the eighth nerve on the stem to help in the identifica tion of the choroi d plexus.
By following the eighth nerve on the stem, the surgeon is led to the CNC. Cerebro spinal fluid ca n be seen emerging from the foramen; this might be enhanced by askin g the anesthetist to raise the intracranial pressure by perfor ming Yalsalva' s maneu ver. The taeni a of the choro id plexus in the lateral recess might have to be divided in order to fac ilitate insertion.
Th e elect rode is inserted with the help of a specially designed introducer, held in place with a small piece of adi pose tissue. Fixation is also aided by a T-shaped Dacron mesh attac hed to the elect rode array. The rece iver stimulator, whic h looks ide ntica l to a Nucl eus coc hlear impl ant, is firmly secu red in a drilled-out bed in the skull, above and behind the mastoid cavi ty.
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Adverseevents did not appear to si gni ficantly differ based onage, sex, or race, although thenumber of non-whites wasrelatively small.
In addition to those adverse events reported above, the follO W ing adverse events have beenreported in fewer than2% of patients who received CLARITIN-D24 HOURExtended ReleaseTablets:
Autonomic Netvous Syslem: Altered lacrimation, flushing, incr eased sweating, mydriasis, thirst.
Body As A Whole: Abnormal visi on, asthenia, back pain , chest pain, conjunctivitis, earache, eye pain, facial edema, fever . tlu-like symptoms, leg cramps, lymphadenopathy. malaise. rigors, tinnitus.
CatdiovascularSystem: Hypert ension. palpitation, tachycardia. Cenlral andPer ipheralNervous Syslem: Convulsions, dysphonia, hyperkinesis, hypert onia, migraine. paresthesia, tremor.
Gaslrointestlnal Syslem: Abdominal distension, altered taste, constipation, diarrhea, dyspepsia, flatul ence, gastritis, stomatitis, tongueulceration, toothache, vomi ting.
LiverandBiliarySystem: Cholelithiasis.
Musculoskeletal System: Arthralgia, musculoskeletal pain. myalgia, tendinitis.
Psychialric: Agitation, depr ession, emotional lability. irritability. ReproductiveSystem: Vaginitis. Resislance Mechanism: Abscess, viralinfection. Respiralory Syslem : Bronchospasm, dyspn ea, epistaxis, hemoptysis, nasal cong estion, nasal irritation, pleurisy, pneumonia,sinusitis, sputum increased, wheezing.
Skin andAppendages: Acne,pruritus. UrinarySyslem: Ol iguria, micturition frequency, urinaryretention, urinarytract infection.
Additional adverse eventsreported with thecombination of teratadine andpseudoephedr ine incl ude abnormal hepatic function, aggressivereaction, anxiety, apathy, contusion, euphoria, paroniria, postural hypotension, syncope, urticaria, vertigo, weight gain.
The following addit ional adverse events have been reported with CLARITIN Tabl et s: abdominal distr ess, alopecia, altered mi cturiti on, altered salivation, amnesia , anaphylaxis, angioneurotic edema, blepharospasm, breast enlargement, breast pain, bronchitis, decreased libido, dermatitis, dry hair, dry ski n, erythemamultiforme, hypoesthesia, impaired concentration, impotence, increased appetite, laryng itis, menorrhagia, nasal dryness, peripheral edema, photosensitivity reaction, purpura, rash, seizures, sneezing, supraventricular tachyarrhythmias, upper respiratory infectio n, urinary~i s c o l o r a t i on .
Pseudoephedrinemay causemi ld CNS stimulation in hypersensitive patients. Nervousness, excitability, restlessness, dizziness, weakness, or insomnia may occur. Headache, drowsiness, tachycardia, palpitation, pressor activity, and cardi ac arrhythmias have been reported . Sympat homimeti c drugs have also been associated with other untoward effects, such as fear, anxiety, tenseness, tremor, hallucinations, seizures, pallor, respir atory difficulty, dysuria, and cardiovascularcollapse.
There havebeenpostmarketing reports of mechanical uppergastrointestinal tract obstructionand esophageal perf orationin pat ients taking a previously mar keted formulation of CLARITIN-D 24 HOUR Extended Rel ease Tablets. In some, butnotall, of thesecases, patients have had known upper gastrointestinal narrowing or abnormal esophageal peristal sis. II is not known whether this reformulation of CLARITIN-D 24 HOUR Extended Rel ease Tabl ets has the potential for this adverse event (see PRECAUTIONS, DOSAGE AND ADMINISTRATION). OVERDOSAGE: In the event of overdosage, general symptomatic and supportive mea sures should be instituted promptly and maintainedfor aslong asnecessary. Treatment of overdosage would reasonably consist of emesis (ipecac syrup), except in patients with impaired consciousness, followed by the administration of activated charcoal to absorb any remainingdrug. If vomi ting is unsuccessful. or contraindicated, gastric lavage should be performed with normal sal ine. Salinecathartics may also be of value for rapid dilution of bowel contents. Loratadine is not eliminated by hemodialysis. It is not known if lcratadlneiseliminated by peritoneal dialysis.
Somnolence, tachycardia, and headache have been reported with doses of40to 180 mg ofloratadine, Inlarge doses, sympathomimetics may give riseto giddiness, headache, nausea, vomiting, sweating, thirst, tachycardia, precordial pain, palpitati ons, difficultyin micturition, muscul ar weakness and tenseness, anxiety, restlessness, and insomnia.Many patients can present a toxic psychosis wi th delusions and hallucinations. Some may devel op cardiac arrhythmias, circulatorycollapse, convulsions, coma, and respiratoryfailure.
The oral medi an lethal dose for the mi xtur e of the twodrugs was greater than 525 and 1B39 mg/kg in mice and rats, respectiveiy (approximately10 and 58times themaximum recommended human daily oral dose on a mg/m' basis). The oral medi an lethal dose for loratadinewas greater than5000 mg/kg in rats and mice(greaterthan 2000 times the maximum recommendedhuman daily oral doseona mg/m' basis). Single oral doses of loratadine showed no effects in rats, mice, andmonkeys at doses ashighas 10times the maximum recommend ed human daily oral doseona mg/m' basis.
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. In an 18-month carcinogenicity study in mice anda 2-year study In rats loratadinewas administered in the diet at doses up to 40 mg lkg (mi ce)and 25mglkg (rats). In the car cinog enicity studies pharrnacokineticassessments werecarrie d out to det ermi neani mal exposureto the drug. AUC data demonstrated that the exposure of mice given40 mglkg of loratadine was 3.6 (Ioratadine) and 18 (active metabolite) times higher thanin humans given the maximum recommended daily oral dose. Exposure of rats given 25 mg/kg of lorat adine was 28 (Ioratadine) and 67 (active metaboli te) times higher than in humans given the maximum recommended dai ly oral dose. Malemicegi ven40 mg/kg had a significantly higher incidence of hepatocellular tumors (combined adenomas and carcinomas) than concurrent controls. In rats, a significantly higher incidence of hepatocell ular tumors (combined adenomas and carcinomas) was obse rved in males given 10 mglkg and in males andfemalesgiven25mg/kg. Theclinical significance of these findings during long-term use of loratacine IS notknown.
Two-year fee ding studies in mice and rats conducted under the auspices of the National Toxicology Programs (NTP) uncovered no evidence of carci nogenic potential of ephedrinesulfateat doses up to 10 and 27 mg/kg, respecti vely (approximately 16% and 100% of the maximum recomm endedhumandail y oral dose of pseudoephedrine sulfateona mg/m' basi s).
In mut agenicity studieswith loratadine alone, there was no evidence of mut agenic potenti al in reverse (Ames) or forward point mutation(CHO-HGPRT) assays, or in the assay for DNA damage (Rat Pri mary Hepatocyte Unscheduled DNA Assay) or in two assays for chromosomal aberrations (Human Peripheral Blood Lymphocyte Clastogenes is Assay and the Mouse Bone Marrow Erythrocyte Micronucleus Assay). In the Mouse Lymphoma Assay, a POSi tive findi ng occurred in the nonactivated but not the activated phase of the stUdy.
Decreased fertility in male rats, shown bylower female conception rates, occurred at 64mg lkg of loratadine(approximatel y 50times the maximum recommended humandaily oraldose based on mg/m') and was reversible with cessation of dosing. Loratadine had noeffect on maleor femalefert ilityor reproduction intheratat24 mg lkg (approximately 20timesthe maximum recommended human daily oral dose ona mg/m' basis).
Pregnancy Cafegory B: The combination product loratadineand pseudoephedrine sulfate was evaluated for teratogenicity in rats and rabbits. There was noevidence of teratogenicity in reproducti onstudieswi th this combination of thesameclinical ratio (1:24)atoral doses upto 150mglkg (approximately 5 times the maximum recommended human dailyoral dose on a mg/m' basis) in rats, and 120 mg lkg (8 times the maximum recommendedhumandaily oraldose ona mg/m' basis) in rabbits. Similarly, noevidence of animal teratogenicity in rats and rabbits was reported at oral doses up to 96 mg lkg of loratadine alone (approximatel y 75 and 150 times, respectively, the maximum human daily oraldoseona mg/m' basis).Thereare, however , noadequateand well-controlled studies in pregnantwomen. Because animal reproduction studiesare not always predictive of human response, CLARITIN-D 24 HOUR Extended Release Tablets should be used duri ngpregnancy only if clearly needed. Nursing Mothers: II is not known if this combination product is excreted in human milk. However, loratadine when administered alone and its metabolite descarboethoxyloratadine pass easily into breast mil k andachieve concentrations that areequi valent to plasma levels, withan AUC••/AUC..,~ratio of 1.17and 0.85 for theparent and active metabolite, respectivel y. Following asingleoral dose of 40mg, asmall amount of lorat adineandmetabolitewas excreted into the breast milk (approximately 0.03% of 40 mg over 48 hours). Pseudoephedr ine administered alonealso distributes into breast milk of the lactating human female. Pseudoephedrine concentrations in mil k are consistently higherthanthose in pl asma. Th etotal amountof drug inmilk as judged by the area under the curve (AUC) is 2 to 3 times greate r than in plasma. The fraction of a pseu doephed rine dose excreted in milk is estimated to be0.4%to 0.7%. A decision should bemade whether to discontinue nursi ngorto discontinue the druQ, takingintoaccount the importance of the drug to themother. Caution should beexercised when CLARITIN-D 24 HOUR Extended Release Tabl ets are admi nistered toa nursi ngwoman. Pedialric Use: Safety andeff ectiveness in children below the age of 12years havenotbeenestablished. ADVERSE REACTIONS: Information onadversereactionsis provided from placebo-controlled studi esinvol ving over 2000 patients, 605 of whom received CLARITlN-D24HOUR Extend ed Release Tablets once daily for up to 2 weeks. In these studies, the incidence of adverse events reportedwith CLARITlN-D 24HOUR ExtendedRelease Tablets was similar to those reported with twice-daily (qI 2h) 120 mg sustained-release pseudoephedrinealone.
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Patients whoareor may become pregnant should be tol d that thi s product should be used in preg nancy or during lactation onl y if the pot ent ial benefit justifies the potential risk to the fetus or nursing infant.
Patients should be instructed notto break or chew thetablet and to take it with a full glass of water (see PRECAUTIONS: Genera l, ADVERSE REACTIONS, DOSAGE ANO ADMINISTRATION). Drug Interactions: Nospecific interacti on studies have beenconducted with CLARI TlN-D 24 HOUR Extended Release Ta blets. However , loratadine(10mg once daily) has beensafel y coadministeredwith therapeutic doses of erythromycin, cimetidine. and ketoconazole in controlled clinical pharmacology studies. All hou gh increased plasma concentrati ons (AUC 0-24 hrs) of loratadi neand/or descarboethoxyloratadine were observed following coadmi nistration of loratadine With each of these drugs in normal vol unteers (n =24in each study), there were no clinically relevant changes in the safety prof ile of loratadine, as assessed by el ectrocardiogr aphic parameters, clinical laboratory tests. vital signs, and adverse events. There were no significant eff ects onQT, intervals, and noreports of sedat ion or syncope. Noeffectson pl asma concentrations of cimetidine or ketoconazole were observed. Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased15% with coadministration of loratadine relativeto thatobserved wi th erythromycinal one. Theclinical relevanceof this differ ence is unknown. These above findi ngs are summarized in the following tabl e:
Effects magnet , which is part of the implanted package. Such an arra nge ment is not co mpatible with the use of magnetic reso nance imaging (MRI). Nearl y all the patients who are likel y to receive ABIs are NF2 sufferers and, as such, are sure to requ ire MRI scanning o n several occasions in the futur e. Th e ABI package has therefore been designed to feat ure a detachable magnet, whic h ca n be rem oved if necessary thro ugh a sma ll skin incision. Alterna tive ly, the externa l co il ca n be held in posi tion by means of a magnet stuck to the skin with adhes ive tape.
Programming
Research in the respo nse characteristics of the cells of the YCN sugges ts that coding strategies employe d with the multi channel coc hlear impl ant might be applica ble to the ABI. The European dev ice, beca use of its larger numb er of electrodes, allows a greater config urat ion of electrode comb inations (i.e., channels). Thi s allows more programming possi bilities , making avai lable a significant num ber of diffe rent pitch percept ions.Th e large numb er of electrodes also means that unwant ed nonaudit ory percepts from an electrode ca n be'program med out, witho ut much effec t on the ove rall performance of the device. 
European Experience
The first patie nt to receive a Europea n des ign ABI was implanted in 1992, after which a total of 10 patie nts from Germany, the UK and Fra nce were implanted as a pilot study. Th is study sugges ted that AB I could indeed restore some deg ree of useful hearing, and so it was decided to expand the study into a multice nter clinical trial in February 1996. Local and Internati onal Ethical Co mmittee approval was obtained together with Com pete nt Authority approv al for five Eu rop ean countries (UK, Ger many, France, Sweden and Spa in). By Nove mber 1996 a total of 17 patients had been imp lanted-lO in the pilot study and 7 as par t of the clin ical tria l. At the time of writing, 14 of these patients have had the ir devices sw itched on, and up to 1998 in Europe , 43 patient s have used such a device.
Results
Th irteen of the 14 patie nts (93 %) in the Euro pea n studies have rece ived auditory sensa tions at initial tun ing, and fo r all of these this has tran slated into some functio nal env iro nme ntal awa reness: ful auditory sensations ca n be detected even in the auditory -a lone condit io n. • Te n of the 14 patients (7 1%) use the device on a dayto-day basis.
A few obse rvations ca n be made regardin g these results. First, in eac h case the number of elec trodes incorporated into the patient's map is less tha n the tota l number of electrodes eliciting an auditory res ponse. In almos t all patient s so me nonaudit ory se nsa tion was perceived on one or more elec trodes before the C-Ieve l was reac hed. Th ese elec trodes were progra mm ed out. Fo r exa mple, one patient obtai ned aud itory sensa tion on every elec trode, but only 14 of the m could be used in the map. It is also ap parent that while most patient s have a varie ty of pitch se nsations , these so unds are often very similar, so that the num ber of pitch-discrete electrodes is usually less than the number of elect rodes in their map s. The best perform er , recentl y impl anted, perceived auditory res po nses fro m 20 electrodes at the very first fitti ng. His map now incorporates 16 cha nnels wi th different place pitches. Two other patients are using mo re than 10 cha nnels, and the others have between 2 and 10 channels inco rporated into their maps. Th e maj ority of pat ients benefit most in the mo nopo lar stimulation mode.
It seems that no explicit or con sistent pitch order ca n be 'expected fro m patient to patie nt across the electrode 115 LASZIG. MARANGOS , SOLLMA NN, RAMSDEN array . It was also noted in one patient that there exis ted a difference in sound quality between a 14-, 11-and 5cha nnel map, with the qualit y beco ming mo re rough as the number of electrodes decreased.
Complications
Two patients in the pilot study died afte r surgery . One had used the imp lant reg ularly for one year but died following surgery for an NF2-related spinal tum or. The othe r died in the perioperative period follo wing tumor removal and ABI insertion as a result of pulm onary em bo lism and pneu monia. In neither case was the co mplica tion related to the impl ant.
On e patient did not res pond to auditory stimulation alone on any of the cha nnels, but she ex perienced somatosen sory phenomena in the face and ipsilateral limbs. Th e auditory evoked brainstem potentials showe d a slightly prol onged latency in this patient, and it see ms likely that in thi s case there was mispl acement of the elec trode array. As she still has a small faci al neuro ma on the same side, an oppo rtunity to rep osition the implant will arise if that tum or ever has to be rem oved.
The first ABI recipi ent reported that the device was of use to her for several months. Thereafter there was a progressive deterioration in the device' s performance, so th at she was obtai ni ng a mixture of audi to ry and nonaud itory percept s and eve ntually became a nonu ser. It was felt that her deteriorat ion might have been due to glios is in the reg ion of the coc hlear nucleus as a result of preoperative irradi ation . Previous treatm ent with the ga mma knife is now a co ntrai ndication to ABI in the Eur opean study .
Conclusions
Earl y experience suggests that the ABI can co nfer co nsiderable benefit to patients with NF2 who have been tot all y deafen ed as a res ult of bilateral ves tibula r schwa nnomas, or because of the surge ry necessary to remove these tumo rs. Almo st all the impl anted patient s in this series were day-to-day users of their implants and reporte d that they wo uld not like to have to do without them . All reported an improved quality of life result ing from enriched aud itory orientation within the enviro nment. All subjects reported an improve d ability in co nver - sation as resu lt of faci litation oflip reading . Furt hermore, speech recognition has been ach ieved to a limited extent in the auditory-alon e mode in so me ind ividual s. Implantation doe s not increase the operati ve risks associated with tumor removal. It doe s, however, lengthen the operatio n becau se of the time req uired for identification of the imp lant site, acc urate posi tio ning of the elec trode and monitoring of the electrically evoked bra instem responses. To date, the per form ance in the AB I group is similar to that seen in cochlear impl ant users in whom those devices work poorly.
